Healthcare & Pharmaceuticals

Gilead abandons filgotinib for rheumatoid arthritis in U.S.

1 minute read

Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease (COVID-19), during the outbreak of the coronavirus disease (COVID-19), in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake

Dec 15 (Reuters) - Gilead Sciences Inc (GILD.O) said on Tuesday it had decided not to pursue the U.S. Food and Drug Administration's approval of its experimental rheumatoid arthritis treatment, filgotinib, following a meeting with the health regulator.

The FDA in August declined to approve filgotinib for rheumatoid arthritis, citing concerns regarding the overall benefit as well as risk profile of the 200 mg dose of the treatment.

Last year, Gilead invested $5.1 billion in a major expansion of its partnership with Belgo-Dutch biotech Galapagos NV (GLPG.AS), banking on the potential of filgotinib and other drugs in development.

Register now for FREE unlimited access to reuters.com
Reporting by Manojna Maddipatla in Bengaluru; Editing by Anil D'Silva

Our Standards: The Thomson Reuters Trust Principles.

More from Reuters